Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProstaSeed is a permanent interstitial brachytherapy source consisting of Iodine-125 adsorbed onto a silver-coated organic filament, encapsulated within a laser-welded titanium capsule. Developed by North American Scientific, it is specifically designed for the treatment of localized prostate cancer through the permanent implantation of multiple seeds into the prostate gland. The device functions by emitting low-energy X-rays and gamma rays (primarily 27-35 keV) as the Iodine-125 isotope undergoes electron capture decay with a half-life of approximately 59.4 days. This localized radiation induces double-strand breaks in the DNA of malignant cells, leading to cell death while sparing distant healthy tissues due to the rapid attenuation of low-energy photons in tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ProstaSeed.